Cereno Scientific participating at ESC Congress 2024 to continue building presence in the global cardiovascular community
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, will participate at the ESC (European Society of Cardiology) Congress in London, August 30–September 2, 2024.
"We look forward to meeting with leaders within the global cardiovascular community at ESC to continue raising awareness about our portfolio of innovative drug candidates, learn about the most recent advances in the cardiovascular field and expand our network among academic and industry actors. With important milestones coming up, the interest in Cereno Scientific and our pipeline has progressed considerably lately, and we are eager to discuss both our progress and future plans with current and potential future collaborators. We are also excited about the fact that Dr. Holinstat will be presenting new preclinical data on our novel drug candidate CS585 at the congress", said Sten R. Sörensen, CEO, Cereno Scientific.
Sten R. Sörensen, CEO; Dr. Rahul Agrawal, CMO and Head of R&D; Dr. Björn Dahlöf, CSO; and Dr. Michael Holinstat, Professor at the Department of Pharmacology, the Department of Internal Medicine, and the Department of Vascular Surgery at the University of Michigan, Director of Translational Research at Cereno Scientific, will attend the congress.
During the congress, meetings will be held with members of Cereno’s Scientific Advisory Board; Dr Bertram Pitt, Chairman of the SAB, Professor Emeritus in Medicine, University of Michigan; Dr. Faiez Zannad, Professor Emeritus of Therapeutics and Cardiology, Université de Lorraine; and Dr. Deepak Bhatt, Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai Health System.
As previously communicated, Dr. Holinstat will present an abstract titled CS585, a novel prostacyclin receptor agonist, demonstrates sustained efficacy in vivo in the prevention of thrombosis, authored by L. Stanger (University of Michigan), A. Rickenberg (University of Michigan), M. Flores (University of Michigan), B. Dahlof (Cereno Scientific) and M. Holinstat (University of Michigan).
Presentation Date: Saturday, 31 August, 13:15–14:15.
Part of Session: Biotherapies in cardiovascular disease: from bench to bedside.
ESC Congress 2024 is where the world's leading cardiology experts convene to transform patient care and advance the field through ground-breaking research, pioneering technologies, and collaborative initiatives. The congress serves as a catalyst for shaping the future of cardiovascular medicine on a global scale. The main theme of ESC Congress 2024 will be 'Personalizing Cardiovascular Care’; a topic devoted to empowering patients through tailored treatments to improve outcomes, reduce risk, and redefine the standard of care.
More information about the event can be found on the ESC Congress website.
For further information, please contact:
Henrik Westdahl, Director IR & Communications
Email: [email protected]
Phone: +46 70-817 59 96
Sten R. Sörensen, CEO
Email: [email protected]
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase II trial is ongoing (patient recruitment closed on July 1st, 2024) to evaluate CS1’s safety, tolerability, and efficacy in patients with the rare disease pulmonary arterial hypertension (PAH). A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. Two initiatives performed during the Phase II trial have shown positive findings suggesting the potential clinical benefit of CS1 in PAH patients. These initial findings are, however, not a guarantee of the final trial results that are expected in Q3 2024. Since January 2024, we are delighted that the FDA´s Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno’s pipeline comprises two additional programs in development through research collaborations with the University of Michigan. Investigational drug CS014 is an HDAC inhibitor in Phase I development as a treatment for arterial and venous thrombosis prevention. The innovative drug candidate represents a groundbreaking approach to antithrombotic treatment. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator – regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without an increased risk of bleeding as documented in preclinical trials. On 28th of June, 2024, Cereno initiated a first-in-human Phase I trial of CS014. Preclinical candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). The Certified Advisor is Carnegie Investment Bank AB, [email protected]. More information is on www.cerenoscientific.com.
